Halozyme Therapeutics, Inc. Aktie News

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with Takeda in December 2025. The agreement provides Takeda with access to Halozyme's ENHANZE® drug delivery technolo...

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye h...

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for pati...

Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term.

SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.

Halozyme Therapeutics is a leader in the subcutaneous drug delivery niche, generating gobs of free cash flow. The company faces patent cliffs ahead for its core products and is actively trying to diversify its offerings.

The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany. The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one o...